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The tumor suppressor phosphatase and tensin homolog deleted in chromosome ten (PTEN) is one of 
the most frequently altered genes in human cancer.  Germline mutations in PTEN result in autosomal 
dominant hamartomatous syndromes, including Cowden Syndrome, a disease that carries an 
increased risk for breast, thyroid, and endometrial cancer. Although genetic and epigenetic alterations 
account for PTEN loss in many cancers, in breast cancer there is a very low incidence of mutation in 
PTEN [1]. Loss of PTEN has been shown to significantly increase the rate of tumor progression in 
multiple mouse models of breast cancer, including ErbB2 induced mammary tumorigenesis, and plays 
an important role in both the epithelial and stromal compartments [2]. These data also correlate with 
human disease progression, as our studies demonstrate that patients with low PTEN protein levels 
have worse disease outcome compared to patients with high levels of PTEN protein (unpublished 
data). However, PTEN mRNA levels in this patient cohort are not predictive of disease outcome.  Our 
observation that 30-40% of the breast cancer patients have a reduction in PTEN protein levels without 
significant alteration of its expression suggests that post-translational events play a key role in 
regulating PTEN protein levels in breast cancer. Thus, a global shRNA screen to identify putative 
regulators of PTEN protein was undertaken in the laboratory. A subset of the identified PTEN 
degradome are components of the ubiquitin-proteasome pathway. Treatment of cells with the 
proteasome inhibitor MG132 results in an increase in total PTEN protein, supporting our observation. 
We chose to study one of these genes, ubiquitin conjugating enzyme E2K (UbE2K), to elucidate its 
mechanism of action in regulating PTEN protein levels. 
Background 
PTEN 
Phosphatase and tensin homolog deleted in chromosome 10 (PTEN) was first described in 1997 as a 
dual lipid and protein phosphatase that selectively dephosphorylates the molecule phosphatidylinositol 
(3,4,5)-trisphosphate to phosphatidylinositol (4,5)-bisphosphate (PIP3 to PIP2) [3,4]. Other targets of 
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Figure 1 PTEN contains 5 domains that define its substrate specificity and function. Its enzymatic 
activity stems from its phosphatase domain, while the C2 domain forms its structural backbone 
[7]. 
PTEN’s phosphatase activity include the proteins IRS1, involved in the IGF signaling pathway, and 
Dishevelled, a member of the Wnt signaling pathway [5, 6]. PTEN is located at locus 10q23 in human 
and codes for a 403 amino acid protein product. It is composed of five functional domains: a 
phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2]-binding domain (PBD), a phosphatase domain, a 
C2 domain, a carboxy-terminal tail and a PDZ-binding domain (Figure 1). Its lipid phosphatase activity 
is vital for its tumor suppressor activity by inhibiting AKT activation. Further studies have elucidated that 
PTEN is a haploinsufficient tumor suppressor, as loss of just one copy of the gene predisposes an 
individual to cancer and accelerates tumorigenesis [8]. This is well documented using mouse models of 
cancer including breast, pancreas, lung, colon, and gliomas models [reviewed in 9]. In hormone 
receptor negative breast cancer patients who had disease recurrence within the first 36 months of 
diagnosis, we observed a significant correlation between low levels of PTEN and worse clinical 
outcome compared to patients with high PTEN levels (Figure 2A, unpublished data). PTEN mRNA 
levels were not predictive of disease outcome in this patient cohort. There are several documented 
human diseases that result from loss of PTEN, including Cowden syndrome, Lhermitte-Duclos disease, 
Bannayan-Riley-Ruvalcaba syndrome, and Proteus and Proteus-like syndromes. Collectively, these 
diseases are known as PTEN hamartoma tumor syndromes. In mice, studies have shown that there is 
a large variation in phenotype depending on how Pten activity is affected [10]. Loss of either Pten’s lipid 
or protein phosphatase activity leads to different phenotypes in mice compared to complete deletion or 
a catalytically inactive form of Pten. This offers a potential explanation for why loss of one tumor 
suppressor can produce such a diverse array of symptoms in patients.  
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Studies in the past have shown that PTEN is important in both the epithelial and stromal compartments 
in preventing tumor progression. Loss of PTEN in one compartment can influence several downstream 
events in the other, primarily resulting from cross-talk between the two compartments, aggravating 
tumorigenesis [11]. Thus, tumors and the surrounding stroma are able to co-evolve with each other, 
promoting further tumor growth. Therefore, it is important to study how PTEN levels are regulated in 
both the epithelium and surrounding stroma in order to have a comprehensive understanding of how 
this important tumor suppressor is regulated under normal condition and in a diseased state. A recent 
Figure 2 A). Low PTEN protein levels in triple negative breast cancer patients correlates strongly with 
worse disease outcome. B) Loss of Pten in stromal fibroblasts using an ErbB2 cancer model resulted in 
a significant increase in tumor growth rate [2]. C) PTEN is subject to multiple post-translational 
modifications including ubiquitination, SUMOylation, phosphorylation, and acetylation that it affects the 




study conducted in our laboratory highlighting the importance of stromal Pten in suppressing tumor 
formation utilized an ErbB2 driven mammary tumor model with deletion of Pten in the stromal 
fibroblasts [2]. Compared to mice with just the oncogenic driver, the concomitant loss of stromal Pten 
significantly increased tumor volume and grade (Figure 2B). 
PTEN is subject to multiple post-translational modifications that can alter its activity, localization, and 
stability (Figure 2C). The primary post-translational modifications that affect PTEN protein stability 
include phosphorylation (Figure 3) and ubiquitination (discussed in detail below). Phopshorylation of 
PTEN by enzymes like GSK3β at Ser362 and Thr366 leads to inhibition of PTEN activity and has been 
implicated in the formation of gliomas [13]. Phosphorylated PTEN must become desphosphorylated 
before it is able to associate with membranes to exert its full functionality. PTEN is also subject to 
SUMOylation by molecules such as SUMO1 at Lys254 and Lys266 to regulate both PTEN activity and 
nuclear localization [14]. Acetylation of the residues between Lys125-128 in the phosphatase domain 
can lead to impairment of PTEN activity [15]. Finally, PTEN is subject to ubiquitination by many different 
ubiquitin ligases such as NEDD4 and MKRN1 with downstream effects ranging from proteasomal 












Figure 3 Several phosphorlyation sites have been mapped that either 
promote or protect PTEN from degradation. GSK3B–mediated 
phosphorylation at Ser362 and Thr366 is known to destabilize PTEN. In 
contrast, RAK mediated phosphorylation of PTEN at Tyr336, or Casein 
Kinase II-mediated phosphorylation at Ser370, Ser380, Thr382, Thr383 




The PI3K/AKT pathway plays a central role in regulating many cellular functions, including protein 
synthesis, cell survival and migration, cell division, and metabolism (Figure 4). Ligand-mediated 
activation of a receptor tyrosine kinase (RTK) leads to activation of PI3K which results in 
phosphorylation of the second messenger PIP2 to PIP3. PIP3 promotes phosphorylation of AKT by 
activating PDK1 [18]. Phosphorylated AKT then signals to many downstream targets, promoting cell 
cycle progression and cell survival via inhibition of pro-apoptotic molecules. PTEN inhibits this pro-
survival signal by dephosphorylating PIP3, thereby attenuating p-AKT signaling. The PI3K-AKT pathway 
has been targeted to treat breast cancer patients, with some proven efficacy. Notable selective PI3K 
inhibitors used in breast cancer therapy include Buparlisib [19], Pilaralisib, and Pictilisib [reviewed in 
20]. Our studies focus on an upstream inhibitor of this pathway, PTEN, that dephosphorylates the 












 Figure 4 Schematic of the PI3K/AKT pathway. The second 
messenger PIP2 is phosphorylated to PIP3 by the enzyme PI3K. PIP3 
then leads to the phosphorylation of AKT, a kinase with many 
downstream targets, including the signal for cell division. PTEN acts 
as the main negative regulator of this pathway by selectively 
dephosphorylating PIP3 to PIP2 [12]. 
 8 
Ubiquitin-Proteasome Pathway 
The ubiquitin-proteasome pathway (UPP) is an important intracellular mediator of a diverse range of 
cellular functions. Ubiquitination alters protein stability, protein-protein interactions, protein activity, and 
subcellular localization, among other properties. The UPP involves three different enzymes that results 
in the covalent linkage of an ubiquitin molecule to the desired substrate (Figure 5A). E1 activating 
enzymes (1 enzyme) bind free ubiquitin through a thioester bond and transfer it to a cysteine residue in 
the active site of an E2 conjugating enzyme (~50 enzymes). These two molecules must dissociate 
before the E2 conjugating enzyme can associate with an E3 ubiquitin ligase (~500 enzymes). The E3 
ligase binds to the substrate molecule and transfers the activated ubiquitin molecule to the substrate 
[reviewed in 21]. Furthermore, E2 conjugating enzymes that associate with E3 ligases containing a 
RING-domain are able to directly transfer the ubiquitin moiety to the substrate, using the E3 ligase for 
structural support [22]. For HECT-domain E3 ligases, the E2 enzyme transfers the ubiquitin moiety to 
the E3 ligase, which subsequently transfers it to the substrate. Substrate proteins can undergo mono-
ubiquitination or poly-ubiquitination and can be linked through multiple different lysine residues on 
ubiquitin (Figure 5B). Of the seven Lys residues in ubiquitin (Ub), Lys48- and Lys11-linked ubiquitin 
chains target proteins for proteasomal degradation and Lys63-linked chains, in general, mediate 































Ubiquitin conjugating enzyme E2K was initially characterized in the brain, where it has particularly high 
expression levels in the frontal cortex and striatum, and is otherwise known as huntingtin-interacting 
protein 2 (HIP2) [24]. UbE2K selectively catalyzes the formation of Lys-48 linked ubiquitin chains, which 
promotes degradation of the substrate by the 26S-proteasome complex [25]. UbE2K has been shown 
to have some E3-independent activity, being able to generate unanchored polyubiquitin chains in the 
absence of an E3 ligase.  However, this activity is dramatically increased in the presence of E3 ligases. 
Figure 5 A) the ubiquitin-proteasome pathway involves 3 enzymes: E1 
activating enzymes, E2 conjugating enzymes, and E3 ligases that cycle to 
produce ubiquitinated substrate based on the specificity of the E3. B) Different 
patterns of ubiquitination can result in different downstream effects, including 





UbE2K in vitro can interact with RING-domain E3 ligases, such as the anaphase promoting complex or 
the BRCA1-BARD1 heterodimer to add polyubiquitin chains to pre-existing monoubiquitinated sites on 
substrates [26, 27]. As a consequence it regulates the proteasomal degradation of targeted substrates. 
Proteasome-Targeted Therapies 
One of the hallmarks of cancer is the loss of cell-cycle regulation that leads to hyperproliferation of 
cells. These transformed cells often overexpress many proteins, some misfolded, and thus have a large 
need for proteasomes to degrade them. Thus, tumor cells are sensitive to the levels of proteasomes 
present [28-30]. Pharmacologic inhibition of proteasome activity using drugs like Velcade has proven 
effective in hematopoietic cancers such as multiple myeloma [31, 32]; however there has been limited 
success in using this approach in solid tumors due to high toxicity. This could be attributed to less 
accessibility of the drug, requiring higher doses in solid tumors to demonstrate any efficacy. Current 
therapies aim to prevent the subunits of the 26S-proteasome from assembling by interfering with 
chaperones vital for their association [33, reviewed in 34]. The results of our studies hope to identify 
novel targets for inhibition to selectively increase PTEN levels by preventing its degradation by the 
proteasome. 
Significance 
Our basic understanding of the signaling pathways, components and physiological conditions that 
regulate PTEN protein stability is limited and poses a major challenge in the field. Because PTEN is 
implicated in a wide variety of cancers, unraveling the underlying mechanisms governing PTEN 
expression and stability is an important step to understand the basic mechanism of its regulation and in 
identifying targets for future therapies. Restoration of PTEN protein levels in tumor cells and in the 
surrounding microenvironment could slow the rate of tumor progression or even reverse the cancerous 
phenotype. This could offer cancer patients with limited treatment options, such as triple negative 
breast cancer patients, with new therapeutic options.  
 11 
Hypotheses 
As our screen identified UbE2K as a negative regulator of PTEN, we hypothesize that depletion or 
targeted disruption of UbE2K in both in vitro and in vivo models will lead to increases in PTEN 
protein levels. We also hypothesize that UbE2K regulates PTEN through the UPP. As we have 
previously shown that Pten levels in both mammary epithelium and stromal fibroblasts are important in 
preventing tumor development, we will study how loss of Ube2k in the epithelial and stromal 
compartments of mouse mammary gland affects its development and eventually mammary 
tumorigenesis.   
Objectives 
Objective 1. Determine if depletion of the negative regulator UbE2K leads to increases in PTEN protein 
levels and study its underlying mechanism  
Objective 2. Study the effects of Ube2k deletion in the mammary epithelium and stromal fibroblasts in 
mice 
Methodology and Rationale 
Objective 1. Determine if depletion of UbE2K, a negative regulator of PTEN leads to increases in 
PTEN protein levels and study its underlying mechanism  
For this study we used the normal human mammary epithelial cell line MCF10A. These cells were 
engineered to express the unstable PTENC124R mutant that has a significantly shorter half-life compared 
to endogenous PTEN. We expressed this unstable mutant of PTEN with the rationale that the effect of 
depletion of a negative regulator on the mutant will be significantly amplified compared to endogenous 
PTEN. We used three different non-overlapping shRNAs targeting the UbE2K transcript to knockdown 
UbE2K. We then used quantitative polymerase chain reaction (qPCR) and sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) to assess the efficiency of the knockdown and to 
determine any changes in the endogenous and mutant PTEN protein levels compared to a negative 
control, expressing scrambled shRNA. To study the mechanism of PTEN degradation, we ectopically 
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expressed UbE2K and PTEN in HEK293t cells and conducted a co-immunoprecipitation to see if 
UbE2K and PTEN associate with each other in the same complex. We also conducted 
immunoprecipitation studies to assess changes in the ubiquitination profile of Pten upon Ube2k deletion 
using mouse embryonic fibroblasts (MEFs) isolated from wild type and Ube2k deleted mouse embryos. 
Objective 2. Study the effects of Ube2k deletion in the mammary epithelium and stromal fibroblasts in 
mice 
We generated Ube2k conditional knockout mice (Ube2kfl/fl) using the Genetically Engineered Mouse 
Modeling core facility at the Ohio State University. We then bred these mice with mice expressing a 
Cre-recombinase for tissue specific deletion of Ube2k. To study the effects of loss of Ube2k in the 
stroma we used Fsp-Cre. This tissue-specific Cre was generated in the lab and is driven by the Fsp 
(fibroblast specific protein) promoter, which is primarily expressed in fibroblasts. We also crossed the 
Ube2kfl/fl mice with MMTV-Cre to study loss of Ube2k specifically in the mammary epithelium. This 
tissue-specific Cre is driven by the MMTV (Mouse Mammary Tumor Virus) promoter, which is 
expressed primarily in the mammary epithelium. We then aged these mice and harvested the 
mammary glands for immunohistochemistry (IHC), Carmine red staining, and Hematoxylin & Eosin 
(H&E) staining.  
Materials and Methods 
Cell Culture: MCF10A cells were grown in phenol-red (PR) containing DMEM/F12 media containing 
human EGF (20 ng/mL, Peprotech), insulin (10 µg/mL, Sigma), cholera toxin (100 ng/mL, Sigma), 
hydrocortisone (0.5 mg/mL, Sigma), horse serum (5%, Invitrogen), and penicillin/streptomycin 
(Invitrogen). Mouse embryonic fibroblasts, MB468, BT474, and T47D cell lines were cultured in PR-
containing media supplemented with fetal bovine serum (10%, Sigma) and penicillin/streptomycin. Cells 
were maintained at 37C and 5% CO2.   
Transfection: HEK293t cells were seeded in 60 mm dishes at a density of 1,000,000 cells. The 
following day, cells were transfected with the respective shRNA plasmid (2.5 µg, pGIPZ, Thermo), 
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psPAX2 (1.25 µg, packaging plasmid, Addgene), and pMD2.g (1.25 µg, envelope plasmid, Addgene) 
using JetPEI reagent (PolyPlus). The viral supernatant was harvested 48 hours later by filtering through 
a 0.45 µm filter. The supernatant was diluted 1:1 with 10% DMEM along with polybrene (8 µg/mL) and 
added to the target cells. After overnight incubation, the infection medium was changed to 10% DMEM 
and incubated for 48 hours. Following this incubation, puromycin was added to the media (2 µg/mL) for 
1 week to select for infected cells. Infection efficiency was also tracked under a fluorescent microscope 
through the expression of GFP. 
RNA: Cells were grown to 70-80% confluency and RNA was isolated using TRIzol reagent (Invitrogen) 
according to the manufacturer’s protocol. cDNA was generated using a High Capacity Reverse 
Transcription kit (Applied Biosystems) according to the manufacturer’s protocol. 2 μg of RNA were 
converted to cDNA. Real-time PCR (qPCR) was conducted using SYBR green SuperMix (BioRad). The 
primers used for qPCR are as follows: 
Gene Forward Primer (5’3’) Reverse Primer (5’3’) 
hPTEN TACACATAGCGCCTCTGACTGG TTGACCAATGGCTAAGTGAAGA 
mPten TTGACCAATGGCTAAGTGAAGA TATACATAGCGCCTCTGACTGG 
hUbE2K CACCATATGAAGGAGGAAGA TCGGGATTTTGTTTGTACTG 
mUbe2k GCGAGGAGACGAGCAAAAATC CAAATAGCCCCTGTGACGGA 
hRNF5 ATGTTTGGAGACTGCTCGGG AATGGCTGGAATCCCCCTCT 
GAPDH TCCTGCACCACCAACTGCTTAG TGCTTCACCACCTTCTTGATGTC 
β-actin TTTGAGACCTTCAACACCCCAGCC AATGTCACGCACGATTTCCCGC 
Table 1 Sequences of primers used to conduct qRT-PCR analysis. Primers were determined using the 
NCBI BLAST program. 
 
Protein: whole cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer (150 mM 
NaCl, 50 mM Tris-HCl pH 8.0, 1% NP-40, 0.05% Sodium Deoxycholate, 0.1% Sodium Dodecyl Sulfate) 
containing protease and phosphatase inhibitors. Lysates were incubated on ice for 30 minutes before 
being centrifuged. The clear supernatant was collected and protein concentration measured using the 
BCA protein assay kit (Pierce, Thermo Fisher). Whole cell lysates were separated on SDS-PAGE gels 
and proteins were transferred to PVDF membranes. After transfer, membranes were blocked for 30 
minutes in 5% milk, 0.1% TBS-Tween and incubated in primary antibody overnight. The following day, 
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membranes were washed twice with 0.1% TBST before incubation in HRP-conjugated secondary 
antibody for one hour and developed using ECL reagent (Thermo). 
Co-culture Assay: Breast cell lines expressing tetrameric Ds-Red (Clonetech) were plated in a 96-well 
plate containing Cultrex basement membrane extract (final concentration 3 mg/mL, Trevigen) along 
with patient-derived fibroblasts. Cells were plated in a 1:1 ratio (12,500 epithelial cells and 12,500 
fibroblasts per well).  PBS was added to the peripheral wells to maintain a constant humidity and 
prevent desiccation of the gel.  The following day, 50 µL of phenol-red free DMEM was overlaid on the 
gel. Absorption readings were taken daily at 592 nm to monitor the growth curve of the Ds-red-tagged 
cancer cells. 
Immunoprecipitation: Whole cell lysates were prepared as described above. 500 μg of protein was 
precleared using IgG/IgA beads (Millipore) for 30 minutes before being incubated with 4 μL of antibody 
overnight. The following day, IgG/IgA beads were added to the mixture for one hour before being 
washed three times. The immunoprecipitated complex was separated on a gradient SDS-PAGE gel 
(BioRad), transferred to a PVDF membrane, and probed with specific antibodies as described above. 
Antibodies used include: PTEN (Catalog # 9559L, Cell Signaling), UbE2K (Catalog # 8226S, Cell 
Signaling), GAPDH (Catalog # sc-25778, Santa Cruz), and β-actin (Catalog # A1978, Sigma). 
Mouse Studies: All mouse experiments were conducted in accordance with the rules and guidelines of 
the Institutional Animal Care and Use Committee (IACUC) of the Ohio State University (Protocol # 
2007A0239-R2). Mammary glands were harvested from the thoracic and inguinal regions and either 
fixed using 4% paraformaldehyde (PFA) for immunohistochemistry or Carnoy’s fixative (60% ethanol, 
30% chloroform, and 10% glacial acetic acid) for carmine red staining (0.2% carmine, 0.5% aluminum 
potassium sulfate, and 1 crystal of thymol). PFA-fixed samples were stored in 70% ethanol until further 
processing, while carmine-stained samples were washed in increasing concentration of ethanol (70% 
ethanol, 95% ethanol, and 100% ethanol, 1 hour each) and then stored in xylene. 
Embryos used for IHC analysis were harvested at embryonic day 13.5 following observation of a plug in 
the mother. Genotyping was conducted by isolating DNA from the embryonic yolk sac following an 
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overnight digestion in lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 1 
µg/mL proteinase K). Embryos and placenta were fixed in formalin for 48 hours and stored in ethanol 
prior to being sectioned and stained.  
To isolate mouse embryonic fibroblasts, we harvested the uterus of the mother at embryonic day 13.5 
and transferred it to sterile PBS in a laminar flow hood. The uterus was opened and each individual 
embryo was isolated using embryo scissors. The yolk sac was used for genotyping as described above. 
Visceral organs were removed and the embryo was then placed in an eppendorf and minced using a 
sterile scalpel. Trypsin was added to the embryos (500 µL, 0.05%) and the suspension was pipetted 
until homogenized. The suspension was then plated onto a 10 cm dish with additional trypsin (5 mL) 
and incubated for 15 minutes at 37°C. The trypsin was neutralized with an equal volume of DMEM 
containing 10% FBS and antiobiotic/antimycotic (complete DMEM) and spun down for 5 minutes. The 
supernatant was aspirated and the cells were suspended in complete DMEM (10 mL) and seeded onto 
10 cm dishes. The cells were then passaged 3T9 (every three days the cells were split 1:3 at a density 
of 900,000 cells per plate) to immortalize the cells. As the cells began to immortalize and slow down 
proliferation, we proceeded to a 3T6 passaging cycle. 
Immunohistochemistry: Freshly harvested tissue was fixed in 4% paraformaldehyde for 48 hours, 
paraffin embedded, cut into 5 μm sections, and stained using an automated cell-stainer (Leica). 
Antibodies used for staining include those stated above and Ki-67 (Catalog # ab16667, Abcam). Ki67 
stains were imaged using the Vectra multispectral microscope (PerkinElmer) and quantified using 
Informa software. In total, 10 ducts per mouse were quantified and averaged together using a batch 







Objective 1. Determine if depletion of UbE2K, a negative regulator of PTEN leads to increases in 
PTEN protein levels and study its underlying mechanism. 
 
1.1 Knockdown of UbE2K in MCF10A cells led to a concomitant increase in PTEN protein levels, but 
not PTEN mRNA levels.  
To assess whether depletion of the putative PTEN regulatory gene has any effect on PTEN in vitro, we 
transduced MCF10A cells, a normal mammary epithelial cell line, with lentivirus that coded for shRNAs 
targeting UbE2K. We assessed the efficiency of three shRNAs in HEK293t cells. Changes in mRNA 
levels of UbE2K were assessed by qRT-PCR with respect to the negative control sample, transfected 
with scrambled shRNA. We chose the shRNAs that most efficiently knocked down UbE2K and used it 
to deplete UbE2K from MCF10A cells. The UbE2K shRNA transduced MCF10A cells were then 
analyzed for changes in PTEN and UbE2K mRNA levels. Our data demonstrated an ~50% or 70% 
decrease in Ube2k mRNA levels, without any marked changes in PTEN mRNA levels. As expected, we 
observed a significant increase in PTEN protein levels in UbE2K depleted cells compared to the control 
(Figure 6A). A similar experiment was repeated in human patient-derived mammary fibroblasts, where 
we observed an increase in PTEN protein following depletion of UbE2K (Figure 6B). When treated with 
cycloheximide, a protein synthesis inhibitor, PTEN degradation was markedly delayed in the UbE2K 
depleted fibroblasts compared to that in the scramble shRNA (shNC) transduced fibroblasts (Figure 
6C).  These data suggest that knockdown of this negative regulator increased the stability of PTEN 
































































Figure 6 A) Knockdown of MCF10A cells using two non-overlapping shRNAs targeted towards UbE2K 
mRNA resulted in increased both PTENC124R and endogenous PTEN protein levels compared to a 
scrambled control. There were no significant changes in PTEN mRNA levels. B) Knockdown of UbE2K 
in patient-derived mammary fibroblasts recapitulated these results. C) Treatment of these fibroblasts 






1.2 DNA damage induced Pten loss was rescued in Ube2k depleted cells 
Wildtype Pten is a relatively stable protein. However, treatment of cells with DNA damaging agents like 
doxorubicin result in Pten destabilization [35]. We wanted to determine whether treatment of cells with 
agents like Doxorubicin would affect Pten levels in the control cells, but not in the Ube2k deleted cells. 
We generated cell lines genetically knocked out for Ube2k by isolating mouse embryonic fibroblasts 
(MEFs) at embryonic day 13.5 from an Ube2k-/+ X Ube2k-/+ breeding. Both wild-type (WT) and knockout 
(KO) lines for Ube2k were generated and immortalized through continuous passaging. We treated wild 
type (WT) and Ube2k KO MEFs, with 5 M doxorubicin for 20 hours, and analyzed RNA and protein 
levels of Pten. We observed a marked decrease in the protein level in WT MEFs, but not in the Ube2k 
KO MEFs (Figure 7B). When we measured RNA levels between the treatment groups, we observed a 
decrease in Pten mRNA levels upon treatment with doxorubicin (Figure 7C). Despite this decrease in 
mRNA, Pten levels in the Ube2k KO MEFs appeared to be affected less than in the WT MEFs, 
























Figure 7 A) Ube2k KO MEFs display higher levels of Pten compared to control MEFs. B) Treatment 
of WT and Ube2k KO MEFs with the drug doxorubicin showed a stabilization of PTEN levels in the 
KO cells compared to the control. C) Treatment of MEFs with doxorubicin reduced Pten mRNA levels. 
 A B 
C 
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1.3 Loss of UbE2K increases PTEN levels in both the cytoplasmic and nuclear compartments 
A defining characteristic of cancerous cells is loss of nuclear PTEN [36-41]. Nuclear PTEN plays a key 
role in chromosome stability, DNA repair, cell cycle arrest and cellular stability. Very little is known 
about PTEN protein turnover in the nuclear compartment. Thus, we wanted to know if the increase in 
PTEN protein we observed in UbE2K depleted cells was the result of stabilization of nuclear PTEN or if 
PTEN was stabilized in both the cytoplasm and nucleus. For this we fractionated MCF10A cells stably 
transduced with shUbE2k or scrambled shRNA, into cytoplasmic and nuclear compartments. We 
observed an increase in both cytoplasmic and nuclear PTEN in MCF10A cells upon UbE2K depletion 
compared to the scrambled shRNA transduced control cells. There was a more pronounced increase in 
the unstable PTENC124R mutant compared to endogenous PTEN, as quantified in the bar diagram 
(Figure 8).  From several iterations of similar experiments, we have found that changes in endogenous 














 Figure 8 Targeted knockdown of UbE2K using two non-overlapping shRNAs in MCF10A 
cells followed by fractionation into cytoplasmic and nuclear compartments revealed an 
increase in both cytoplasmic and nuclear PTEN in the knockdown cells compared to a 
scrambled control. 
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1.4 Loss of UbE2K alters the ubiquitination profile of PTEN 
UbE2K has been previously shown to specifically ubiquitinate substrates for proteasomal degradation. 
We next wanted to determine whether UbE2K mediates PTEN ubiquitination using Ube2k knockout 
MEFs. For this, we immunoprecipitated PTEN from WT and Ube2k KO MEFs.  Following 
immunoprecipitation and immunoblotting with a PTEN-specific antibody, we noticed a dramatic 
difference in the profile of Pten in WT compared to KO cells, where high molecular weight Pten bands, 
presumably ubiquitinated, were lost in the KO cells (Figure 9). Further studies are being conducted to 
validate that these differences are due to ubiquitination rather than another post-translational 
modification. However, these results are promising because the only difference between these two 

















Figure 9 Immunoprecipitation of Pten from whole cell lysates of 
WT and Ube2k KO MEFs using a Pten antibody revealed 
differences in the Pten ubiquitination profile. These changes were 
maintained under Pten-destabilizing conditions by treatment with 
doxorubicin. 
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1.5 UbE2K may interact with the RNF5 E3 Ligase to promote PTEN degradation 
In order to understand how the ubiquitin-proteasome pathway regulates PTEN levels, it is important to 
identify the E3 ligase(s) that partners with UbE2K to promote degradation of PTEN. While there are 
approximately 50 identified E2 conjugating enzymes, there are hundreds of identified E3 ligases. Thus, 
identifying the E3 ligases that complex with UbE2K to mediate the ubiquitination of PTEN is an 
important step in elucidating the entire pathway. A proteomics screen conducted in Dr. Michael 
Ostrowski’s lab at The Ohio State University to identify PTEN interacting proteins revealed RNF5 as an 
E3 ligase that interacts with PTEN. Previous studies using a yeast-two hybrid system identified RNF5 
as a binding partner of UbE2K, via the RING-domain in the E3 ligase [42]. Based on this information, 
we wanted to see whether RNF5 regulates PTEN protein stability similarly to UbE2K. We knocked 
down RNF5 in MCF10A cells using three different shRNAs and analyzed changes in mCherry-tagged-
PTENC124R levels and endogenous PTEN levels. To further analyze our cell populations, we conducted 
FACS analysis to observe changes in mCherry intensity. Compared to parental and scrambled control 
lines, the cell lines infected with RNF5 shRNA showed an increase in mCherry intensity, confirming that 
there was an increase in PTENC124R levels in these cells (Figure 10). We then validated this increase in 
PTEN levels through western blotting and qPCR. We observed increases in both PTENC124R and 
endogenous PTEN protein along with a concomitant decrease in RNF5 levels. Similarly, we observed 
no significant changes in PTEN mRNA while there was a marked reduction in RNF5 mRNA levels 
(Figure 11).  We are currently performing fractionation experiments on these RNF5 knockdown cells to 
see if we can recapitulate the increase in nuclear PTEN we observed upon knockdown of UbE2K. We 
also plan to repeat cycloheximide experiments in these cells to see if depletion of RNF5 renders PTEN 



















Figure 10 FACS analysis of MCF10A cells knocked down for RNF5 revealed an increase in 
mCherry intensity, correlating with an increase in PTENC124R levels compared to a scrambled 
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Figure 11 Depletion of RNF5 in MCF10A cells resulted in an increase in PTENC124R and endogenous 




Objective 2. Study the effects of Ube2k deletion in the mammary epithelium and stromal fibroblasts in 
mice 
2.1 Ube2k neohypomorphs are viable and mimic the in vitro effect of Ube2k depletion  
To understand the role of this putative regulator in a complex organism, we generated mice with 
conditional knockout alleles for Ube2k in the Leone lab, following IACUC guidelines (Protocol 
2007A0239-R2).  The targeting vector was obtained from KOMP (EUCOMM), where the Cre-Lox 
recombination system was used for targeted deletion of Ube2k (Figure 12). Briefly, mouse embryonic 
stem cells were electroporated with a vector containing an Ube2k allele with two loxP sites flanking 
exon 4 of the gene.  The vector also contained a lacZ cassette and a neomycin resistance cassette 
flanked by FRT sites (see Figure 12, targeted allele). ES cells positive for the targeting vector were 
selected for using neomycin and were inserted into a pseudo-pregnant mouse, producing chimeric 
mice. When the allele became germline, these mice were bred with ACTFLPe mice to delete the lacZ 












 Figure 12 Targeting vector for the Ube2k allele.  LoxP sites were introduced flanking exon 
4 of the Ube2k gene and a LacZ-Neo Cassette was introduced between exons 3 and 4 
flanked by FRT sites. 
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We first studied the cassetted Ube2k neohypomorph (Ube2kneo/neo) mice. Immunohistochemical 
analysis of day 13.5 embryos revealed Ube2k to be absent in the neohypomorphs, whereas Pten levels 
were increased compared to WT littermates (Figure 13). These mice are viable and fertile; however, 
they are runted compared to their wild-type littermates (Figure 14A). We next harvested and analyzed 
different tissues from 60 day old male and female neohypomorphs. Analysis of the liver sections 
revealed predominantly nuclear localization of Ube2k in the hepatocytes of the WT mice, which is 
completely lost in the neohypomorphs. A striking increase in nuclear localization of Pten was observed 
in the neohypomorphs, demonstrating a reciprocal relationship between the two proteins in vivo (Figure 
14B, C). This finding also corroborates our in vitro data where we observed an increase in nuclear 
PTEN after depletion of UbE2K using shRNAs.  
Figure 13 Immunohistochemical analysis of E13.5 embryos revealed a loss of Ube2k and a 
concomitant increase in Pten levels. 
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We have also harvested mammary glands from two month old female mice and performed dual-
immunofluorescence on the mammary gland to study the relationship between Pten and Ube2k levels. 
We found that Ube2k (in red) is highly expressed in the nuclei of the mammary epithelial cells of the 
wildtype mice, and is significantly reduced in the neohypomorphs. Analysis of Pten (in green) levels 
demonstrated markedly higher levels of nuclear Pten in the mammary epithelium of the neohypomorph 
compared to that in the wild-type littermates (Figure 15). We also observed this reciprocal relationship 
in areas of the stroma where Ube2k is expressed. This observation further supports our hypothesis that 























Figure 14 A) Disruption of Ube2k results in a runted developmental phenotype B) Ube2k shows 
primarily nuclear localization in WT mice which is lost in the neohypomorphs C) loss of Ube2k 
resulted in nuclear localization of PTEN in the hepatocytes of 60 day old mice. 
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2.2 Mice with conditional knockout alleles for Ube2k recapitulated our in vitro results and 
produced phenotypic abnormalities. 
To delete the lacZ-neo artificial cassette, we bred Ube2kneo/neo mice (targeted allele, Figure 12) with 
ACTFLPe mice and obtained mice with an Ube2k floxed allele (Ube2kfl/fl). We then generated whole 
body knockout mice (KO) for Ube2k by breeding the Ube2kfl/fl mice with Sox2-Cre mice. Genotyping 
was conducted using a three-primer PCR system that recognized the WT, floxed, and knockout alleles 
represented by 370 bp, 447 bp and 617 bp PCR products as shown in Figure 16. We have noted that 
the Ube2k KO mice have severe developmental defects compared to the neohypomorphs (Figure 
17A). Most KO pups die within two days of birth and weigh less than littermate WT and heterozygous 
(Het) pups (Figure 17B). Ube2k KO mice appear to be born at numbers lower than the predicted 
Mendelian ratio.  We have harvested tissues from P2 (post natal day 2) pups and stained them with 
Haematoxylin and Eosin (H&E) to assess any histological changes. We have also determined the 
status of Ube2k and Pten protein levels by IHC to assess any changes in Pten levels and to see 
Figure 15 Dual-immunofluorescence analysis of 2 month old WT and neomorph mammary 
glands revealed an inverse relationship between Ube2k and Pten protein levels (note the 




whether or not we can recapitulate our in vitro data where we observed a reciprocal relationship 











Figure 16 Schematic used for genotyping Ube2k conditional mice along with a representative gel 
showing the banding pattern for all three potential PCR products. 
Figure 17 A) Whole-body Ube2k KO pups are runted at after birth compared to WT and heterozygous 
(Het) littermates and typically die within two days of birth. B) Ube2k KO pups weigh less than WT or Het 
littermates.  
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2.3 Loss of Ube2k in the stromal fibroblasts leads to decreased branching in the mammary 
gland 
Because whole body knockout of Ube2k resulted in early post-natal lethality, we generated conditional 
knockout mice by deleting Ube2k specifically in the stromal fibroblasts using Fsp-cre. For this we bred 
mice harboring conditional alleles for Ube2k with mice expressing the stroma-specific recombinase, 
Fsp-Cre. We aged the experimental (Fsp-Cre; Ube2kfl/fl) and control (Ube2kfl/fl) littermates to three 
months of age, when mammary gland development has completed. The mammary gland undergoes 
dynamic changes throughout the adult life of the females due to hormonal changes that occur as a 
result of the estrus cycle [43].  Thus, it is important to ensure that all mice were harvested at the same 
stage of the estrus cycle. We chose to harvest the experimental and control mice at diestrus because 
this is the most proliferative phase for the mammary gland. We hypothesized that this will amplify any 
differences in proliferation resulting from the presence or absence of stromal UbE2K that in turn is 
expected to reciprocally regulate Pten levels. We observed decreased branching in the experimental 
mice when compared with an age-matched control. Immunohistochemistry for Pten and Ube2k 
performed on consecutive sections showed that Ube2k deletion was specific to the stromal fibroblasts 
and that Pten levels increased in both the epithelium and stroma (Figure 18). We are currently 
performing experiments to determine whether this difference arises from increased levels of Pten, 
which would suppress cell proliferation, or from an off target effect of Ube2k deletion in the stromal 










Figure 18 A) Whole mounts of mammary glands from 12 week old mice at diestrus and stained with 
Carmine red revealed a decrease in alveologenesis upon deletion of Ube2k in stromal fibroblasts. B) 
UBE2K IHC demonstrates fibroblast-specific deletion of Ube2k and shows a concomitant increase in 



























2.4 Loss of Ube2k in the stromal fibroblasts of the mammary gland results in decreased 
proliferation of mammary epithelial cells. 
After observing a difference in the branching pattern of the mammary gland in mice with a stromal 
deletion of Ube2k, we performed IHC on mammary gland sections from the same mice to determine 
whether markers of cell proliferation were altered in the experimental group. After staining the sections 
for Ki67, a cell proliferation marker, we observed a significant reduction of Ki67 positive cells in the 
Ube2k-deleted mice compared to that in the controls (Figure 19). This decrease in proliferation 
explains the reduced branching phenotype we observed and supports our hypothesis that reduction of 
Ube2k leads to an increase in Pten in the fibroblasts, and cross-talk between the altered stroma and 
epithelium might have led to suppression of cell proliferation.  Additional studies are in progress to 
validate if altered Pten levels are the key mediator of epithelial proliferation.   
These findings were tested using an in vitro co-culture model in parallel. Breast cancer cell lines with a 
DsRed reporter were cultured in matrigel with patient-derived fibroblasts expressing either basal levels 
of UbE2K or depleted UbE2K using shRNA. The proliferation rate of the epithelial cells was markedly 
decreased when co-cultured with fibroblasts containing reduced levels of UbE2K compared to control 
fibroblasts (Figure 20). These data suggest that depletion of stromal UbE2K can affect the proliferation 
rate of the epithelium. We have yet to establish that this effect is dependent on PTEN levels, but our in 
vitro data suggests that this could be the mechanism involved. We also plan to study the mechanism of 
how loss of stromal UbE2K affects proliferation in the epithelium. Identifying this signaling mechanism 














Figure 19 Ki-67 IHC of 12 week mammary gland in diestrus confirmed that epithelial proliferation in the control 
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MB 468 + 786BI shNC
























BT474 + 786BI shNC






















T47D + 786BI shNC
T47D + 786BI shUbE2K
Figure 20 Co-culture of DsRed tagged epithelial cells with patient-derived fibroblasts 
revealed a decrease in proliferation upon loss of UbE2K in the fibroblasts.  
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Discussion 
Our concerted effort to identify factors regulating PTEN protein stability has led to the identification of 
an E2 conjugating enzyme, UBE2K, and alludes to a role of the ubiquitin-proteasome pathway in PTEN 
degradation. We observed a reciprocal relationship between UbE2K and PTEN levels in cells, 
suggesting that UbE2K negatively regulates PTEN. These results were validated in both in vitro and in 
vivo models. These findings could be important clinically, as low PTEN levels correlate with poor 
disease outcome in almost all cancers, including triple negative breast cancer. Furthermore, post-
translational modifications that compromise the normal function of PTEN could potentially explain how 
individuals without a genetic mutation in PTEN could become predisposed to develop cancer.  
In vitro knockdown of UbE2K using non-overlapping shRNAs in MCF10A cells resulted in an increase 
in PTEN protein independent of its mRNA level. Furthermore, UbE2K depletion resulted in an increase 
in the amount of nuclear PTEN. It is important to note that Ube2k is predominantly localized in the 
nucleus, particularly in the hepatocytes and mammary epithelium.  Nuclear PTEN has been implicated 
in maintaining genomic stability, which is frequently compromised in cancer cells. Our finding suggests 
that Ube2k could be involved in Pten turnover in the nucleus and thus stabilization of PTEN by targeting 
UbE2K could be beneficial for cancer patients. However, it is important to conduct additional studies to 
suggest this possibility, as UbE2K is expected to have several other targets. We hypothesize that 
nuclear PTEN is degraded in the presence of UbE2K. Because UbE2K is specific for proteasomal 
degradation and not translocation like some other E2 enzymes, it is likely that blocking degradation 
accounts for the increase in nuclear PTEN and not a failure to export PTEN from the nucleus. It has 
already been shown that monoubiquitination of PTEN at Lys13 and Lys289 regulates shuttling between 
the cytoplasmic and nuclear compartments [39]. Meanwhile, polyubiquitination at Lys289 by molecules 
like NEDD4 and MKRN1 have been shown to target PTEN for proteasomal degradation. Thus, it will be 
important to map the Lys residues targeted by PTEN by its potential binding partner RNF5 to gain 
important insight into how these genes regulate PTEN levels. 
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We have also observed alteration in the Pten ubiquitination profile in Ube2k KO MEFs, suggesting that 
Ube2k mediates the ubiquitination of Pten. A second proteomics study conducted in our group to 
identify PTEN interacting proteins has identified RNF5, a Ring Finger E3 ligase, as a potential E3 ligase 
that binds to PTEN.  Previous studies using a yeast-two hybrid assay system have shown RNF5 is a 
binding partner of UbE2K [42]. Based on this information we have depleted RNF5 in MCF10A cells, and 
observed a similar increase in PTEN levels, supporting our hypothesis that UbE2K and RNF5 might 
work in concert to regulate PTEN degradation. Interestingly, previous studies have shown that 
increased RNF5 levels correlate with poor disease outcome in breast cancer patients [44].  We are 
currently performing additional studies to validate these observations and determine whether 
overexpression or knockdown of RNF5 alters the ubiquitination profile of PTEN similar to UbE2K. More 
long-term experiments consist of generating conditional and whole-body knockout mice for Rnf5 and 
generating MEFs to study the role of Rnf5 both in vitro and in vivo—similar to those performed with 
Ube2k KO mice and MEFs. Several other E3 ligases for PTEN have also been reported in the 
literature, including NEDD4, MKRN1, and WWP2 that could be revisited in the context of UbE2K.   
In general, our in vivo experiments in mice recapitulated our in vitro observations. We observed 
negative staining of Ube2k by IHC in both whole-body and conditional knockout mice with a 
concomitant increase in Pten. Loss of stromal Ube2k in the mammary gland had an effect on Pten 
levels in the epithelium and suppressed proliferation. While these results are promising and corroborate 
our hypothesis, we still need to demonstrate that Ube2k deletion and subsequent Pten protein 
stabilization in the stromal fibroblasts is the key determinant of the reduced proliferation rate of the 
mammary epithelium in these mice. It will be important to determine whether these changes in Pten 
levels in the stromal fibroblasts are able to suppress proliferation of mammary tumor cells. We plan to 
use the ErbB2-neu tumor model similar to the one used in Trimboli et al. in an FVB/N background to 
see whether increasing Pten levels via deletion of Ube2k in the stroma alters the progression of the 
tumors. Based on our hypothesis, we predict that increasing Pten levels will slow down or inhibit the 
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growth of these tumors, as researchers have previously shown that stromal Pten suppresses mammary 
epithelial tumors.  
Our studies aim to elucidate the pathways responsible for PTEN turnover in cells, as this area remains 
relatively unexplored and may provide insight into PTEN pathophysiology. Identifying these enzymes 
could provide novel targets for treatment using therapeutics such as proteasome inhibitors or targeted 
siRNA delivery.  Furthermore, because PTEN is one of the most frequently lost tumor suppressors in 
human cancer, our findings may potentially translate into other cancers such as endometrial, 
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